To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 01.07.2020
Page 1/1
Doc.-No. EIP-0027
Revision 2

Californian Proposition 65

MEGGLE Products:
- Lactose Monohydrate (Ph. Eur. / USP-NF / JP): CapsuLac® 60, FlowLac® 90, FlowLac® 100, GranuLac® 70, GranuLac® 80, GranuLac® 140, GranuLac® 200, GranuLac® 230, PrismaLac® 40, SacheLac® 80, SorboLac® 400, SpheroLac® 100, Tablettose® 70, Tablettose® 80, Tablettose® 100
- Lactose Monohydrate (USP-NF / Ph. Eur. / JP): Lactose monohydrate Low Endotoxin
- Inhaler Grade Lactose Monohydrate (USP-NF / Ph. Eur. / JP): InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 150, InhaLac® 160, InhaLac® 230, InhaLac® 250, InhaLac® 251, InhaLac® 400, InhaLac® 500
- Co-processed excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, RetaLac®, StarLac®

Substances known to the State of California to cause cancer or birth defects or other reproductive harm are not used for the production of above mentioned products.

The above mentioned products are safe as pharmaceutical excipient and as food e.g. in food supplements.

Residues and contaminants in above mentioned products are monitored. The products as such or the used compounds comply with the relevant pharmaceutical monographs and relevant food laws and cause no significant risk of harm when they are used.

Best regards

MEGGLE GmbH & Co. KG

Dr. Stefan Dreiheller